TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8405016

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of pantoprazole (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of pantoprazole (40 mg)
Number of subjects: 12
Study: 3535986

Group type: EXPERIMENTAL
Intervention: Large dose of caffeine (15 mg X kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Small dose of caffeine (10 mg X kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 30178066

Group type: EXPERIMENTAL
Intervention: Flaccid unilateral facial paralysis
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Unilateral moderate to severe postparalytic facial nerve syndrome
Number of subjects: 298

Group type: COMPARATOR
Intervention: Monocular blindness
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Post-facial reanimation
Number of subjects: 298
Study: 28230029

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 + nedaplatin 20 mg/m2, administered on day 1 and 8 with 21 days per cycle for 3 cycles
Number of subjects: 63

Group type: COMPARATOR
Intervention: 5-fluorouracil 500 mg/m2 + cisplatin 20 mg/m2, administered on day 1-5 with 21 days per cycle for 3 cycles
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 24760484

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 489
Study: 22357022

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) based stress resilience training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological monitoring during VR training
Number of subjects: 0
Study: 20532476

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metformin (RECORD trial)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rosiglitazone (RECORD trial)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sulfonylurea (RECORD trial)
Number of subjects: 50
Study: 18176213

Group type: EXPERIMENTAL
Intervention: Povidone-iodine preoperative showers (liquid detergent-based povidone-iodine 10% 2 hours before surgery)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no special instructions for showering before surgery)
Number of subjects: 114
Study: 15877299

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fenofibrate 250 mg/d
Number of subjects: 21
Study: 12746736

Group type: EXPERIMENTAL
Intervention: Haloperidol (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study: 10225074

Group type: EXPERIMENTAL
Intervention: Oxygen in nitrous oxide 1:2
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oxygen in air
Number of subjects: 42
Study: 8723576

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg intravenous (i.v.) twice weekly for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 100 IU/kg subcutaneous (s.c.) twice weekly for 3 weeks (with a single i.v. bolus of 200 IU/kg at the first s.c. dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatment groups (i.v. and s.c. epoetin alfa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (both routes)
Number of subjects: 0
Study: 1914619

Group type: EXPERIMENTAL
Intervention: Terfenadine, 120 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6362676

Group type: EXPERIMENTAL
Intervention: Kelfiprim (trimethoprim 250 mg + sulfalene 200 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Co-trimoxazole (trimethoprim 320 mg + sulfamethoxazole 1600 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Kelfiprim
Number of subjects: 46

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 46
Study: 30621653

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 202
Study: 29210520

Group type: EXPERIMENTAL
Intervention: MMN (18 vitamins and minerals including 250 μg iodine per day)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: LNS (20 g/day of small-quantity lipid-based nutrient supplements with 250 μg iodine)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: IFA (60 mg iron and 400 μg folic acid per day)
Number of subjects: 1320
Study: 26815360

Group type: EXPERIMENTAL
Intervention: Alcohol + caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol + placebo caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo alcohol + caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alcohol + placebo caffeine
Number of subjects: 0
Study: 24059254

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active control (alternative activities)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory training (young-old)
Number of subjects: 80
Study: 21790793

Group type: EXPERIMENTAL
Intervention: Moisturizer containing 0.025% licochalcone
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1% hydrocortisone
Number of subjects: 72
Study: 19353398

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 20599

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 20599

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 20599

Group type: EXPERIMENTAL
Intervention: Family history of coronary disease
Number of subjects: 20599

Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 20599
Study: 18186579

Group type: EXPERIMENTAL
Intervention: Crude rhubarb treatment (3 g, tid, p.o)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Crude rhubarb treatment
Number of subjects: 40
Study: 15073700

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (100 mg/kg after anesthetic induction, 100 mg/kg on CPB, and 100 mg/kg after protamine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg after anesthetic induction, 10 mg/kg on CPB, and 10 mg/kg after protamine)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 11752035

Group type: EXPERIMENTAL
Intervention: Dialysis to dry weight
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACEi) with enalapril 5 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined volume reduction with dialysis and ACEi
Number of subjects: 19
Study: 9721002

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x day(‐1), given in 4 x 6‐g doses of 5 g creatine monohydrate and 1 g glucose for 5 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 8620951

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2506966

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 254

Group type: COMPARATOR
Intervention: Topical steroids and mydriatics (Control)
Number of subjects: 254
Study: 4244871

Group type: EXPERIMENTAL
Intervention: Purified ampicillin (Penbritin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpurified ampicillin (Penbritin)
Number of subjects: 0
Study: 31596612

Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy Lithotripsy (FURL)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Miniaturized Percutaneous Nephrolithotomy (MPCNL)
Number of subjects: 220
Study: 28258434

Group type: EXPERIMENTAL
Intervention: USG-guided corticosteroid injection (40 mg/2 mL methylprednisolone acetate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blinded corticosteroid injection (40 mg/2 mL methylprednisolone acetate)
Number of subjects: 40
Study: 26364080

Group type: EXPERIMENTAL
Intervention: Laser-induced collapse before vitrification
Number of subjects: 270

Group type: COMPARATOR
Intervention: Vitrification without collapsing (Control)
Number of subjects: 270
Study: 23123790

Group type: EXPERIMENTAL
Intervention: low volume, low intensity exercise
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: high volume, low intensity exercise
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: high volume, high intensity exercise
Number of subjects: 320

Group type: COMPARATOR
Intervention: no-exercise control
Number of subjects: 320
Study: 21544005

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin (RBV) at a moderate dose (8.33 mg/kg/dose q 8 hours on day 1, 5 mg/kg/dose q 8 hours on days 2-10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin (RBV) at an escalated dose (33 mg/kg on day 1, then 16 mg/kg/dose q 6 hours for 4 days, and 8 mg/kg/dose q 8 hours for 3 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18297416

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus gabapentin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 40
Study: 16594804

Group type: EXPERIMENTAL
Intervention: E-mail users and nonusers discussing e-mail and traditional communication methods
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional media
Number of subjects: 68
Study: 15754838

Group type: EXPERIMENTAL
Intervention: Positive HUT (P group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Prolonged asystole (PAS group)
Number of subjects: 176
Study: 11385119

Group type: EXPERIMENTAL
Intervention: Chronic lead exposure
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 23
Study: 9061991

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no therapeutic touch)
Number of subjects: 0
Study: 7953415

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 30
Study: 2887134

Group type: EXPERIMENTAL
Intervention: Orogastric lavage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipecac-induced emesis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control ingestion
Number of subjects: 10
Study: 31944487

Group type: EXPERIMENTAL
Intervention: High dose tDCS (2.5 mA for 30 min)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low dose tDCS (0.034 mA for 30 min)
Number of subjects: 130
Study: 30139638

Group type: EXPERIMENTAL
Intervention: IBI-10090 (5 μL injection of 517 μg)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Prednisolone acetate 1.0% (1 drop 4 times daily for 3 weeks)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IBI-10090
Number of subjects: 181

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 181
Study: 26990899

Group type: EXPERIMENTAL
Intervention: Telemedicine-enabled research informed consent
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard face-to-face (F2F) research informed consent
Number of subjects: 131
Study: 25721132

Group type: EXPERIMENTAL
Intervention: Sensor-based interactive exercise training (twice a week for 4 weeks)
Number of subjects: 39
Study: 23553157

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (1.3 g/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: High-sodium diet (3.8 g/d)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Black girls
Number of subjects: 67

Group type: COMPARATOR
Intervention: White girls
Number of subjects: 67
Study: 20957858

Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Number of subjects: 0
Study: 18226761

Group type: EXPERIMENTAL
Intervention: Culturally relevant messages, community member referral networks, and adjustment to community realities
Number of subjects: 0
Study: 16321668

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 45
Study: 14600695

Group type: EXPERIMENTAL
Intervention: Dentin adhesive
Number of subjects: 34

Group type: COMPARATOR
Intervention: Calcium hydroxide cement
Number of subjects: 34
Study: 10914620

Group type: EXPERIMENTAL
Intervention: HRT decision aids
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Provider discussion about menopause
Number of subjects: 156
Study: 8991493

Group type: EXPERIMENTAL
Intervention: 2 x 25 mg clomipramine hydrochloride tablets (Noristan Ltd.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anafranil 2 x 25 mg tablets (clomipramine HCl; Ciba‐Geigy (Pty) Ltd.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 x 10 mg clomipramine hydrochloride tablets (Noristan Ltd.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anafranil 5 x 10 mg tablets (clomipramine HCl; Ciba‐Geigy (Pty) Ltd.)
Number of subjects: 0
Study: 1389190

Group type: EXPERIMENTAL
Intervention: Thiopental with infusion of sufentanil 0.1 microgram/kg/hr
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopental with infusion of fentanyl 1 microgram/kg/hr
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhalation of 0.25% to 2% isoflurane
Number of subjects: 30
Study: 3999630

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (including diuretics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 0
Study: 31733809

Group type: EXPERIMENTAL
Intervention: Perseus A500 (redesigned)
Number of subjects: 16

Group type: COMPARATOR
Intervention: GE Aespire 7900 (conventional)
Number of subjects: 16
Study: 30473540

Group type: EXPERIMENTAL
Intervention: Liraglutide injection: 0.6‐1.2 mg/day, 12 weeks, n=52
Number of subjects: 127

Group type: COMPARATOR
Intervention: Metformin (oral metformin: 1000‐1500 mg/day, 12 weeks, n=75)
Number of subjects: 127
Study: 27125172

Group type: EXPERIMENTAL
Intervention: e-learning program
Number of subjects: 44

Group type: COMPARATOR
Intervention: traditional classroom lecture
Number of subjects: 44
Study: 24081874

Group type: EXPERIMENTAL
Intervention: Care-ILI-QoL
Number of subjects: 125

Group type: COMPARATOR
Intervention: SF-12v2 Acute Form
Number of subjects: 125
Study: 22449295

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 1370
Study: 20400552

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Intensive comparison therapy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study: 18533791

Group type: EXPERIMENTAL
Intervention: Synthetic sponge based on polylactic‐polyglycolic acid technology (FIS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Natural coral derivative (COR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-grafted control
Number of subjects: 8
Study: 15990986

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (OASIS 1)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Ceftriaxone/metronidazole (OASIS II)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 349
Study: 12393986

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with or without radiotherapy (26 epirubicin, 19 epirubicin + ifosfamide)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with or without radiotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Surgery with or without radiotherapy
Number of subjects: 88
Study: 10654875

Group type: EXPERIMENTAL
Intervention: 5.0 mg/day bisoprolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day bisoprolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy control subjects receiving 5.0 mg/day bisoprolol
Number of subjects: 11
Study: 7751412

Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg/day
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 2190040

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nifedipine (30 mg)
Number of subjects: 17
Study: 628896

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) of the calves
Number of subjects: 95

Group type: COMPARATOR
Intervention: No specific form of prophylaxis (Control)
Number of subjects: 95
Study: 31807856

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856 (IBS-D subgroup)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856 (IBS-C subgroup)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Saccharomyces cerevisiae CNCM I-3856 (IBS-M subgroup)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30472215

Group type: EXPERIMENTAL
Intervention: CST-AET (Coping Skills Training for Adherence to Endocrine Therapy)
Number of subjects: 400

Group type: COMPARATOR
Intervention: General health education intervention (comparison condition)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CST-AET
Number of subjects: 400
Study: 27787700

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.4 mg) and Indomethacin (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Desmopressin and Placebo
Number of subjects: 23
Study: 25919012

Group type: EXPERIMENTAL
Intervention: Men not on ART prior to surgery
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Post-operative weeks 1-3
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Post-operative week 6
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Post-operative week 12
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Men with HIV plasma VL > 50,000 copies/ml
Number of subjects: 223

Group type: COMPARATOR
Intervention: Men with healed MC wounds
Number of subjects: 223

Group type: COMPARATOR
Intervention: Men on ART with undetectable plasma VL
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Men with ART-induced undetectable plasma VL
Number of subjects: 223
Study: 23371002

Group type: EXPERIMENTAL
Intervention: Full-endoscopic surgery
Number of subjects: 192

Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 192
Study: 21250973

Group type: EXPERIMENTAL
Intervention: Revaccination with non-live vaccines after chemotherapy, starting as early as 3 months post-chemotherapy.
Number of subjects: 0
Study: 19283649

Group type: EXPERIMENTAL
Intervention: Physical exercise; details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified
Number of subjects: 0
Study: 17583186

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 10965639

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment for BED
Number of subjects: 162
Study: 8989743

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nondialysis day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: First hour of hemodialysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Second hour of hemodialysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postdialysis period
Number of subjects: 10
Study: 1291593

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (4 g of vaginal cream containing 2.5% natural progesterone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Number of subjects: 80
Study: 6712445

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infrared radiation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pulsed ultrasound (US)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo ultrasound (US)
Number of subjects: 10
Study: 30863474

Group type: COMPARATOR
Intervention: Fentanyl matrix
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 108
Study: 29843644

Group type: EXPERIMENTAL
Intervention: COACH intervention (integrated care model with primary care provider and Aging Worker)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Enhanced Care‐as‐Usual (eCAU)
Number of subjects: 2400
Study: 27741123

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy (RAGT) combined with rehabilitation therapy (RT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rehabilitation therapy (RT) alone
Number of subjects: 56
Study: 24820311

Group type: EXPERIMENTAL
Intervention: Conservatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberals
Number of subjects: 0
Study: 22682044

Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene liners (5.0 Mrad gamma-irradiation and heat treated)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Non-cross-linked polyethylene liners
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Cross-linked polyethylene liners
Number of subjects: 230
Study: 20976738

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic (STN) stimulation
Number of subjects: 45
Study: 18514630

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) treatment, 70.6 kcal/day (8 g of essential AAs) given at 10:00 am and 5:00 pm
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) treatment
Number of subjects: 41
Study: 15838723

Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: apraclonidine 1%
Number of subjects: 40
Study: 12417888

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chlorpheniramine 8 mg
Number of subjects: 21